Bristol-Myers Squibb Company

Healthcare · Drug Manufacturers - General

Overall research band Above average

Quality Mixed

Valuation Exceptional

Balance sheet Very weak

Market confirmation Strong

One-minute company read

What this report can tell you now

What the company does

Bristol-Myers Squibb Company is a global biopharmaceutical company engaged in the research, development, licensing, manufacturing, and worldwide commercialization of medicines. Its therapeutic focus includes hematology, oncology, cardiovascular health, immunology, fibrotic diseases, neuroscience, and infectious diseases such as COVID-19. Key products in its portfolio are Revlimid for multiple myeloma, Eliquis for stroke risk reduction and treatment of thromboembolic disorders, Opdivo and Yervoy for various cancers, Pomalyst/Imnovid for multiple myeloma, Orencia for rheumatoid and psoriatic arthritis, Sprycel for chronic myeloid leukemia, Abraxane for chemotherapy, Reblozyl for anemia in beta thalassemia, Empliciti for multiple myeloma, Zeposia for multiple sclerosis, Breyanzi for large B-cell lymphoma, Inrebic for myelofibrosis, and Onureg for acute myeloid leukemia. The company distributes its pharmaceutical products through wholesalers, distributors, pharmacies, retail outlets, hospitals, clinics, and governmental organizations.

The current research profile is Mixed Setup, with high valuation support. This is a starting point for investigation, not a forecast or recommendation.

Strongest visible signal

Recent market behavior is the strongest visible confirmation. Check whether it agrees with the underlying business evidence.

What to investigate next

Read the latest filing or company update, check the period behind the metrics, and investigate the dimension with the weakest band above.

Before you draw a conclusion

Read the latest filing or company update.
Check the financial period behind each metric.
Investigate the weakest score band and any missing evidence.

Headline fundamentals

A small set of signals worth checking

ROIC17.1%Model input; read with the evidence status and period context.

Operating margin26.3%Model input; read with the evidence status and period context.

Revenue CAGR · 4 years1.0%Model input; read with the evidence status and period context.

FCF margin26.7%Model input; read with the evidence status and period context.

Go deeper when you need to

Compare the right companies, understand what changed, and monitor the evidence.

Peer contextCompare companies using the appropriate economic neighborhood.

Evidence detailSee exact inputs, source context, and model-aware metrics.

HistoryReview score and research changes over time.

MonitoringKeep the questions, risks, and changes that matter in view.

The public report remains useful on its own. Premium adds depth, history, comparison, and monitoring.